A new study, published in the journal npj Acoustics, suggests that focused sound waves may help reduce delusions in people ...

Pancreatic cancer remains a major treatment challenge in South Korea. According to the company, 9,748 people were diagnosed with the disease in 2023, and the five-year relative survival rate was 17%.

Unibail-Rodamco-Westfield (URW.PA) on Wednesday reported a 2.2% drop in total turnover for the first nine months of 2026 to €2.23 billion from €2.28 billion last year. On a like-for-like basis, ...

European stocks closed notably lower on Thursday as concerns over spending on AI infrastructure, Middle East and Russia-Ukraine conflicts, and elevated oil prices hurt investors sentiment. Worries ...

Myriad Genetics ( MYGN) announced new data from the ongoing MONSTAR-SCREEN-3 study demonstrating the potential of its whole-genome sequencing-based Precise MRD platform to detect molecular residual ...

Multi-platinum singer-songwriter Tinashe has announced that she will embark on a headlining tour of North American in 2027.

On Thursday, S&T Bancorp, Inc. ( STBA) reported higher income in the third quarter of 2026, compared to the same quarter last year. Net income in the third quarter went up to $38.60 million or $1.09 ...

Propanc Biopharma ( PPCB) announced that its Board of Directors has approved a 1-for-10 reverse stock split of the company's issued and outstanding common shares, aimed at restoring compliance with ...

Groupe ADP expects Paris passenger traffic to decline slightly in 2026 and anticipates recurring EBITDA at the lower end of its EUR 2.3 billion to EUR 2.35 billion guidance range. ADP.PA closed ...

Accor upgraded its 2026 recurring EBITDA guidance to between EUR 1.270 billion and EUR 1.285 billion, compared with its previous range of EUR 1.260 billion to EUR 1.285 billion. The company also ...

Swedish property company AB Sagax (SAGA-A.ST,SAGA_D.ST,SAGA_A.ST,SAGA_B.ST) on Wednesday reported higher rental revenue and profit for the first nine months of 2026. The company also raised its ...

While ovarian cancer is the initial target, Ernexa believes the underlying platform could potentially be adapted for other solid tumors and additional oncology applications. The company said its ...